All Stories

  1. Cognitive deficits in Parkinson’s disease with excessive daytime sleepiness: a systematic review
  2. Risk assessment of wandering behavior in mild dementia
  3. Acceptability of an Advance Directive That Limits Food and Liquids in Advanced Dementia
  4. The Effect of Dance on Depressive Symptoms in Nursing Home Residents
  5. What Is Discomfort in Persons With Dementia Who Are Agitated?
  6. Reductions of Antipsychotic and Hypnotic Medications in Namaste Care
  7. Palliative care in dementia
  8. Involvement in Activities and Wandering in Nursing Home Residents With Cognitive Impairment
  9. Behavioral Problems of Seniors in an Emergency Department
  10. Nursing Home Residents Dying With Dementia in Flanders, Belgium: A Nationwide Postmortem Study on Clinical Characteristics and Quality of Dying
  11. Apathy and Weight Loss in Nursing Home Residents: Longitudinal Study
  12. Severe impairment of circadian rhythm in Alzheimer's disease
  13. Severe impairment of circadian rhythm in Alzheimer’s disease
  14. Antipsychotics Do Not Have To Be Used “Off Label” in Dementia
  15. Treatment of Behavioural Disorders
  16. Is Your Nursing Home a Battlefield?
  17. Antibiotics and Mortality in Patients with Lower Respiratory Infection and Advanced Dementia
  18. Toward Better Terminology of Behavioral Symptoms of Dementia
  19. Relationship between symptoms of depression and agitation in nursing home residents with dementia
  20. International Association of Gerontology and Geriatrics: A Global Agenda for Clinical Research and Quality of Care in Nursing Homes
  21. Decision-making in patients with severe dementia and pneumonia: cross-national perspectives
  22. Futility Discussion Revisited
  23. Dementia
  24. 14.1 Palliative medicine in dementia
  25. Namaste care and dying in institutional settings
  26. Modifiable Factors Related to Abusive Behaviors in Nursing Home Residents With Dementia
  27. The Clinical Course of Advanced Dementia
  28. Do We Need Another Dementia Pain Scale?
  29. Evaluations of end of life with dementia by families in Dutch and U.S. nursing homes
  30. Behaviors in Advanced Dementia
  31. Culture Change for Residents With Dementia
  32. Is Aggression a Common Symptom of Dementia?
  33. P4‐338: Feasibility of evidence‐based brain healthy nutrition in clinical practice with individuals and private groups
  34. Development of a Scale to Measure Quality of Visits With Relatives With Dementia
  35. Development of a Scale to Measure Quality of Visits With Relatives With Dementia
  36. TREATMENTS IN PATIENTS DYING WITH DEMENTIA: A CROSS‐CULTURAL PERSPECTIVE
  37. Wandering behavior in veterans with psychiatric diagnoses residing in nursing homes
  38. Agitation and Resistiveness to Care Are Two Separate Behavioral Syndromes of Dementia
  39. P‐084: Memory preservation nutrition intervention to reduce risk and delay progression: Clinical practice report
  40. Family Member Perception of Quality of Their Visits With Relatives With Dementia: A Pilot Study
  41. Management of neuropsychiatric symptoms Nathan Herrmann
  42. Defining severe dementia with the Minimum Data Set
  43. Effects of Continuous Activity Programming on Behavioral Symptoms of Dementia
  44. P4–416: Evidence–based memory preservation diet™ ©2005 to reduce risk and slow progression of Alzheimer's disease (AD)
  45. Advanced Dementia Research in the Nursing Home: The CASCADE Study
  46. The Validity and Reliability of Scales for the Evaluation of End-of-Life Care in Advanced Dementia
  47. Models of Physician Education for Alzheimer's Disease and Dementia: Practical Application in an Integrated Network
  48. Looking Beyond Aggressiveness and Dementia
  49. Treatment of Behavioral Disorders
  50. [P‐157]: Memory preservation diet (C) 2005 for reducing risk and slowing progression of Alzheimer's disease
  51. Ten Myths About Decision-Making Capacity
  52. Management of Constipation in Residents With Dementia: Sorbitol Effectiveness and Cost
  53. End-of-life care and dementia
  54. Caregiver burden in dementia care: Prevalence and health effects
  55. S4-04-02 Assessing benefits of treatment at end of life
  56. P2-353 Continuous activity programming enhances quality of life in residents with dementia
  57. Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease
  58. P1-380 Evidence based nutrition, exercise, cognitive rehabilitation & stress management interventions for Alzheimer's disease: treatment or prevention?
  59. End-of-Life Care in Nursing Homes: Is the Glass Half Empty or Half Full?
  60. End-of-life care and bereavement: effect on family carers
  61. Health Professionals' Views on Standards for Decision‐Making Capacity Regarding Refusal of Medical Treatment in Mild Alzheimer's Disease
  62. Pitfalls in Assessment of Decision-Making Capacity
  63. Ethics and Research in Long-Term Care: A Position Statement from the American Medical Directors Association
  64. ENHANCED AMBULATION AND QUALITY OF LIFE IN ADVANCED ALZHEIMER'S DISEASE
  65. A Pain Assessment Tool for People With Advanced Alzheimer’s and Other Progressive Dementias
  66. Constipation Medications
  67. Are Nursing Home Residents with Dementia Aggressive?
  68. Alzheimer Disease
  69. Is Percutaneous Endoscopic Gastrostomy Really Better?
  70. Caring for Persons With Dementia:
  71. Advance Care Planning by Proxy for Residents of Long‐Term Care Facilities Who Lack Decision‐Making Capacity
  72. End-of-Life Care in Dementia: A Review of Problems, Prospects, and Solutions in Practice
  73. Dementia
  74. Evaluation of Pain in Cognitively Impaired Individuals
  75. Scales for Evaluation of End-of-Life Care in Dementia
  76. Nutritional Management of Individuals with Alzheimer's Disease and Other Progressive Dementias
  77. Sundowning and Circadian Rhythms in Alzheimer’s Disease
  78. Management of severe Alzheimer's disease and end-of-life issues
  79. Differential Circadian Rhythm Disturbances in Men with Alzheimer Disease and Frontotemporal Degeneration
  80. Target Outcomes for Long‐term Oral Health Care in Dementia: a Delphi Approach
  81. End-of-Life Care for Patients With Advanced Dementia
  82. Locking the Stable Door After the Horse Left
  83. Tools for evaluation of end-of-life care in dementia
  84. Circadian rhythm disturbances in advanced dementia: Diagnostic specicity
  85. Acupuncture to treat anxiety and depression in Alzheimer's disease and vascular dementia: A pilot feasibility and effectiveness trial
  86. Effects of smoking and alcohol on Alzheimer disease: The mirage study
  87. Dimensions of Decreased Psychological Well-Being in Advanced Dementia
  88. Hospice Care Patients With Advanced Progressive Dementia Ladislav Volicer and Ann Hurley. New York: Springer Publishing Company, 1998, 305 pp., $US 48.95.
  89. PC12 cells transfected with a C-terminal fragment of the amyloid precursor protein (APP C-100), exhibit enhanced sensitivity to the calcium ionophore A23187, and diminished sensitivity to hydrogen peroxide
  90. Enhanced inhibition of free radical-induced deoxyribose breakdown by Alzheimer brain homogenates
  91. Development and testing of the resistiveness to care scale
  92. Dedication
  93. Assessment of Behavioral Symptom Management in Demented Individuals
  94. Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia
  95. Determination of thiobarbituric acid reactive products formed from deoxyribose in biological samples
  96. Determination of thiobarbituric acid reactive products formed from deoxyribose in biological samples
  97. Persistent Vegetative State in Alzheimer Disease
  98. Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease
  99. Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease
  100. Postnatal changes of brain monoamine levels in prenatally malnourished and control rats
  101. Neurotoxicity of free-radical-mediated serotonin neurotoxin in cultured embryonic chick brain neurons
  102. LOCALIZATION OF MULTIPLE HISTOCHEMICAL MARKERS OF OXIDATIVE INJURY IN PROJECTION NEURONS IN ALZHEIMER CORTEX
  103. Effect of Fever-Management Strategy on the Progression of Dementia of the Alzheimer Type
  104. Effect of Fever-Management Strategy on the Progression of Dementia of the Alzheimer Type
  105. 292 Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease
  106. 127 Recommending treatment decisions for Alzheimer patients
  107. Reaching consensus: The process of recommending treatment decisions for Alzheimer's patients
  108. Impact of Dementia Special Care Units: Resource Use and Outcomes
  109. Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease
  110. Effect of prenatal malnutrition on release of monoamines from hippocampal slices
  111. Effect of Seizures on Progression of Dementia of the Alzheimer Type
  112. Stability of o-phthalaldehyde—sulfite derivatives of amino acids and their methyl esters: Electrochemical and chromatographic properties
  113. Prenatal protein malnutrition effects on the serotonergic system in the hippocampal formation: An immunocytochemical, ligand binding, and neurochemical study
  114. Less Slippery
  115. Palliative fever management in Alzheimer patients
  116. Effects of medication on parotid salivary flow rates in an individual with dementia of the Alzheimer type
  117. Book Review Geriatric Pharmacology By Rubin Bressler and Michael D. Katz. 689 pp. New York, McGraw-Hill, 1993. $49.95. 0-07-007660-X
  118. Heterogeneity of Brain Gene Expression in Alzheimer's Diseasea
  119. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease
  120. Assessment of discomfort in advanced Alzheimer patients
  121. Book Review Aging and Ethics Edited by Nancy S. Jecker. 394 pp. Clifton, N.J., Humana Press, 1991. $32.50. Set No Limits: A rebuttal to Daniel Callahan's proposal to limit health care for the elderly Edited by Robert L. Barry and Gerard V. Bradley. 134...
  122. "Ideal" SCU Not So Ideal
  123. Laminar Alterations in γ‐Aminobutyric AcidA, Muscarinic, and β Adrenoceptors and Neuron Degeneration in Cingulate Cortex in Alzheimer's Disease
  124. Modification of Brain Guanine Nucleotide‐Binding Regulatory Proteins by Tryptamine‐4,5‐Dione, a Neurotoxic Derivative of Serotonin
  125. Involvement of free radicals in dementia of the Alzheimer type: A hypothesis
  126. Additional psychiatric illness by diagnostic interview schedule in male alcoholics
  127. Preparation, reactivity, and neurotoxicity of tryptamine-4,5-dione
  128. Neurotoxic effects of partially oxidized serotonin: tryptamine-4,5-dione
  129. Meeting Nutritional Needs of Alzheimer Patients Who Pace Constantly
  130. The Short-Term Effects of In-Hospital Respite on the Patient With Alzheimer's Disease
  131. Acute Hepatic Damage in Rats Impairs Metharbital Metabolism
  132. Cerebrospinal fluid levels of angiotensin- converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: A correlative study
  133. Hospice Approach to the Treatment of Patients With Advanced Dementia of the Alzheimer Type
  134. Distribution of the molecular forms of acetylcholinesterase in human brain: Alterations in dementia of the Alzheimer type
  135. Systematic regional differences in the cholinergic innervation of the primate cerebral cortex: Distribution of enzyme activities and some behavioral implications
  136. Serotoninergic System in Dementia of the Alzheimer Type
  137. Epinephrine-induced cyclic AMP production in skin fibroblasts from patients with dementia of Alzheimer type and controls
  138. Serotonin and 5-Hydroxyindoleacetic Acid in CSF
  139. Aminopyrine Breath Test and Zonal Hepatic Damage in Rats
  140. Development of Reversible Hypertension During Disulfiram Therapy
  141. Development of reversible hypertension during disulfiram therapy
  142. Effect of Dietary Restriction and Stress on Body Temperature in Rats
  143. Aging in the Food-restricted Rat: Body Temperature, Receptor Function, and Morphologic Changes in the Brain
  144. Variation in length of time to development of alcoholism by family history of problem drinking
  145. Beta-adrenergic receptor sensitivity in cultured vascular smooth muscle cells: Effect of age and of dietary restriction
  146. Effect of ethanol administration and withdrawal on benzodiazepine receptor binding in the rat brain
  147. Presence of Two Benzodiazepine Binding Sites in the Rat Hippocampus
  148. Self Reports on Alcohol use and Compliance with Antihypertensive Medication
  149. Bradykinin receptors in isolated intestinal smooth muscle
  150. GABA receptors in alcoholism
  151. Cyclic Nucleotide Immunohistochemistry
  152. Cyclic Nucleotide Immunohistochemistry
  153. Cerebrospinal Fluid GABA and Cyclic Nucleotides in Alcoholics with and without Seizures
  154. Age-related changes of cyclic nucleotide levels in rat brain regions
  155. Alcohol and cardiovascular disorders
  156. Thermoregulation in Spontaneously Hypertensive Rats: Effects of Antihypertensive Treatments
  157. GABA levels and receptor binding after acute and chronic ethanol administration
  158. Epinephrine Disposition in Control and Asthmatic Subjects
  159. Effect of ethanol and stress on gamma-aminobutyric acid and guanosine 3′, 5′-monophosphate levels in the rat brain
  160. Mineralocorticoid-Induced Hypertension in Patients with Orthostatic Hypotension
  161. Effect of Nadolol in Treatment of Hypertension
  162. Circadian Rhythm of Cyclic Nucleotide and GAB A Levels in the Rat Brain
  163. Cyclic nucleotide levels in brains of control and hypertensive rats
  164. UPTAKE, METABOLISM AND RELEASE OF CATECHOLAMINES IN THE LUNG
  165. Metabolic Factors Affecting Brain Cyclic Nucleotides
  166. Effect of Angiotensin Converting Enzyme Inhibition on Blood Pressure, Plasma Renin Activity and Plasma Aldosterone in Essential Hypertension *
  167. Cardiovascular changes associated with stress during hospitalization
  168. Cyclic nucleotide levels in the rat striatum and cerebellum—
  169. Effect of Histamine on Cyclic AMP Levels in Control and Antigen-Sensitized Guinea Pig Lungs
  170. Relationship between brain levels of cyclic nucleotides and γ-aminobutyric acid during ethanol withdrawal in rats
  171. ETHANOL-STIMULATED FORMATION OF A NOVEL NUCLEOTIDE IN RAT LIVER IN VITRO
  172. Norepinephrine Uptake in Guinea Pig Lung
  173. Effect of aging on cyclic AMP levels and adenylate cyclase and phosphodiesterase activities in the rat corpus striatum
  174. Adenosine triphosphate-derived nucleotide formation in the presence of ethanol
  175. Effect of Epinephrine on Cyclic AMP Levels and Adenylate Cyclase and Phosphodiesterase Activities in Control and Antigen-Sensitized Guinea Pig Lungs
  176. Adenylate Cyclase Activity in Heart and Lung: Effect of Epinephrine and Histamine in Control and Sensitized Guinea Pigs
  177. Academic achievement in pharmacology and use of audiovisual aids
  178. Effect of morphine sulfate on adenylate cyclase and phosphodiesterase activities in rat corpus striatum
  179. Effects of Arterial Hypoxemia and Splenic Nerve Stimulation on Myocardial Adenosine 3,5’-Monophosphate in Dogs
  180. Interactions of Ethanol with Cyclic AMP
  181. Sensitized guinea-pig lung: Altered adenylate cyclase stimulation by epinephrine
  182. Kinetics of norepinephrine metabolism in the rat heart In vivo
  183. Effect of ethanol on cyclic AMP levels in the rat brain
  184. Localization of the Cyclic AMP System in the Arterial Wall
  185. Penetration of angiotensin II into the brain
  186. Effect of catecholamines and angiotensin on cyclic AMP in rat aorta and tail artery
  187. The Effect of Urethane Anesthesia on the Cardiovascular Action of Angiotensin II
  188. The effect of angiotensin on the turnover rate of norepinephrine in the rat heart
  189. Beeinflussung der alimentären Hyperlipidämie des Schweines durch Phospholipide
  190. The Accumulation of H<sup>3</sup>-Serotonin in Platelet-free Rats
  191. Effect of phenoxybenzamine on the turnover rate of heart norepinephrine
  192. Effect of drugs on turnover rate of heart norepinephrine
  193. Brain Amines and Temperature Regulation
  194. Studies on 6-azauridine and 6-azacytidine—IV.
  195. THE MODE OF ACTION OF SCHIZANDRA CHINENSIS
  196. Presence of Blood in Tears during the Mecholyl Test
  197. Neurotoxic Oxidative Metabolite of Serotonin